clinical trial · NCT05558124
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute·phase1·recruiting·n = 18
Acute Myeloid LeukemiaVyxeosGemtuzumab Ozogamicin
brief summary
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
started
Feb 16, 2023
primary completion
Apr 1, 2027
completion
Apr 1, 2027
last updated
Feb 27, 2026
official title
A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol